North Korea Reports "Giant Stride" in Medical, Scientific Research
Posted on: Saturday, 31 December 2005, 06:00 CST
Text of report in English by North Korean news agency KCNA
Pyongyang, 31 December: This year has witnessed a giant stride in scientific researches into protecting and improving the life and health of the people, and in the efforts to introduce scientific successes into clinical practice amid the care of government of the Democratic People's Republic of Korea.
Kim Myong-dok, a department director of the Ministry of Public Health, told KCNA that scientists of the Academy of Medical Science have recently succeeded in developing injection nyuamin, poly-amino acid sap efficacious for post-operation and post-illness weakness, tuberculosis, hepatitis and other diseases, and taxol injection potent for various kinds of cancers, and in manufacturing them by industrial method.
Scientists of the Academy of Koryo Medical Science found out diagnosis and treatment methods according to kinds of chronic pancreatitis and developed chinjihwang (steamed foxglove) fine tablets efficacious for the disease. Its efficacy is 89.2 per cent.
Basing themselves on the traditional Koryo treatment method, they invented therapeutics for spontaneous gangrene and neuroparalysis without using drugs. Its curative efficacy is more than 85 per cent.
The government has paid deep attention to the work for putting the methods of prevention, diagnosis and treatment on a scientific basis and the research into longevity of people.
The efforts were crowned with successes in developing agents for diagnosing viral diseases and many kinds of health food, including huimang No 2, pine pollen nutritive pills and Kumgang natural health water. They are efficacious for nervous system disorders and good for the improvement of health.
The department director added that the successes are attributable to the socialist public health system of the country centred on the popular masses.
Source: BBC Monitoring Asia Pacific
Related Articles
- AMT Successful in Preclinical Treatment of DMD
- -Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments-
- HHS Secretary Sebelius Highlights Michigan's MHA Keystone Center in Inaugural Health Care 'Success Story' Report
- Santhera Receives First Product Approval: Health Canada Approves Catena(R) for Treatment of Friedreich's Ataxia
- Nektar Commences Phase 2 Trial of NKTR-118 (Oral PEG-Naloxol) Evaluating Efficacy and Safety As Treatment for Opioid-Induced Bowel Dysfunction
- DFW Value-Driven Health Care Collaborative Launched for Treatment of Diabetes
- CSC and 'Connecting for Health' Team Successfully Demonstrates Nationwide Health Information Network Prototype
- Health Talks Success
- Community Heart Health Program Successful
- Carilion Health System Successfully Launches Park City Solutions' Dx Lab Connect Portal
 |
 |
User Comments (0)
RSS Feeds